AI-Empowered Fundus Imaging: Intelligent Platform for Diagnosis, Treatment, and Early Warning of Fundus Diseases

What this Trial Is About

High myopia, a condition where the eye has a severe refractive error, is increasingly common worldwide and especially prevalent among students in urban China. This condition can lead to serious vision problems and complications such as cataracts, glaucoma, and macular degeneration. Pathological myopia, characterized by elongation of the eye and thinning of the retina, often results in posterior scleral staphyloma (PSS), which can severely affect vision and potentially cause blindness. Researchers are developing an intelligent multimodal screening system that combines advanced imaging technologies including the Optos non-mydriatic ultra-wide-angle laser scanning ophthalmoscope, B-scan ultrasonography, and optical coherence tomography (OCT). This system uses artificial intelligence to precisely identify and assess fundus diseases, focusing on pathological myopia and PSS. It also aims to create a vision prediction model to help doctors tailor diagnosis and treatment plans, predict vision decline, and improve early intervention. Participants will undergo comprehensive eye examinations using color fundus photography, B-scan ultrasound, and OCT imaging. Detailed baseline data including demographic information, health status, eye history, and ocular measurements will be collected. The study will gather data from October 2024 to April 2026, followed by AI modeling analysis from April to October 2026. This research supports improved prevention, diagnosis, and management of pathological myopia, and may enhance telemedicine services to reach remote populations.

AI-Empowered Fundus Platform